George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 8.50
Ask: 10.00
Change: 0.00 (0.00%)
Spread: 1.50 (17.647%)
Open: 9.25
High: 9.25
Low: 9.25
Prev. Close: 9.25
NBB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

24 Jan 2023 07:00

RNS Number : 5985N
Norman Broadbent PLC
24 January 2023
 

Norman Broadbent plc

("Norman Broadbent", "NBB" or the "Group")

Trading Update

Norman Broadbent (AIM: NBB), a leading London quoted Executive Search and Interim Management firm offering a diversified portfolio of integrated Leadership Acquisition & Advisory Services, provides the following unaudited trading update for the three months ended 31 December 2022 ("Q4 2022") and the year ended 31 December 2022 ("FY22").

Q4 2022 Highlights

· Group Net Fee Income ("NFI") up 29% to £2.34m (Q4 2021: £1.81m)

· NFI up 40% compared to the average for the previous 3 quarters of £1.67m

· Edinburgh office established ahead of plan to bolster position in Scotland

· Sub-let over capacity in London office with income entirely offsetting cost in 2023 of newly opened Aberdeen and Edinburgh offices

 

FY22 Highlights

· NFI up 27% to £7.34m (FY 2021: £5.8m)

· Positive EBITDA expected to be approximately £100k, up c.£400k on FY 2021's LBITDA of £303k

· Highest expected annual NFI and EBITDA figures since FY 2019 and Company very much back to pre-pandemic levels

· Very positive run rate carry over from Q4 2022 into Q1 2023 with forward contracted revenue up 27% to £1.28m (Q1 2022: £1.01m)

Kevin Davidson, Group CEO of Norman Broadbent, commented:

"I am delighted with our Q4 2022 performance and the achievements of the team in 2022 as a whole. As planned, the Company generated positive annual EBITDA whilst also growing headcount significantly, thus building the platform for continued profitable growth in future years. This includes a number of fee generating hires made in Q4 2022 who will begin delivering revenue in Q1 2023. The quality and seniority of mandates has also been consistently rising over 2022 with the average fee per engagement increasing by 50% over that period. 

There has been significant change across the business over the past 18 months which has been driven and embraced by the entire team. We have very high levels of engagement and collective ambition for the future of Norman Broadbent.

We are aiming to deliver annual EBITDA of £1.25 million in 2025 through organic growth whilst continuing to seek acquisition opportunities. While the economic headwinds remain challenging, I am confident that the necessary foundations are in place to enable us to achieve this target."

For further information please contact:

Norman Broadbent plc

Kevin Davidson, CEO

Mehr Malik, CFO

 

+44 (0) 20 7484 0000

 

Shore Capital (Nominated Adviser and Broker)

Tom Griffiths / Tom Knibbs (Corporate Advisory)

Henry Willcocks (Corporate Broking)

+44 (0)20 7408 4090

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFERLFIVFIV
Date   Source Headline
25th Apr 20247:00 amRNSQ1 2024 Trading Update
24th Apr 20247:00 amRNSSmall Cap Awards nomination
15th Apr 20243:18 pmRNSNotification of major holdings
8th Apr 202412:11 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20244:01 pmRNSNotification of major holdings
28th Mar 20247:00 amRNSPosting of ARA & Notice of AGM
27th Mar 20247:00 amRNSFinal Results
26th Mar 20244:07 pmRNSNotification of major holdings
20th Mar 20241:36 pmRNSNotice of Results & Investor Presentation
18th Mar 20244:33 pmRNSNotification of major holdings
18th Mar 20244:04 pmRNSNotification of major holdings
12th Mar 20243:33 pmRNSAIM Rule 17 Schedule Two (g) Update
22nd Jan 20245:32 pmRNSNotification of Major Holdings
16th Jan 20247:00 amRNSTrading Update
21st Nov 202310:06 amRNSNotification of Major Holdings
20th Nov 202310:45 amRNSDirector/PDMR shareholding
15th Nov 20239:54 amRNSNotification of Major Holdings
15th Nov 20239:43 amRNSNotification of Major Holdings
10th Nov 20237:00 amRNSDirector/PCA Dealing
9th Nov 20232:25 pmRNSDirector/PDMR Shareholding
2nd Nov 20238:43 amRNSConversion Of Outstanding Convertible Loan Notes
12th Oct 20237:00 amRNSQ3 2023 Trading Update
10th Oct 202311:03 amRNSNotification of Major Holdings
9th Oct 20237:00 amRNSSurrender and Granting of Options
28th Jul 20237:00 amRNSGrant of Options
24th Jul 20237:00 amRNSInterim Results
11th Jul 20237:00 amRNSH1 2023 Trading Update
30th Jun 20237:00 amRNSSAYE Option Plan & Director Holding
29th Jun 20234:28 pmRNSResult of AGM
5th Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 20237:00 amRNSDirectorate changes
31st May 20237:00 amRNSFinal Results
22nd May 20237:00 amRNSQ1 2023 Trading Update
19th May 202312:55 pmRNSPartial Repayment of Convertible Loan Note
24th Jan 20237:00 amRNSTrading Update
10th Jan 20237:00 amRNSDirectorate Change
17th Nov 20224:42 pmRNSTR-1: Notification of major holdings
14th Nov 20227:00 amRNSIssue of Equity
1st Nov 20227:00 amRNSUpdate and Change of Board role
10th Oct 20225:30 pmRNSTR-1: Notification of major holdings
31st Aug 20227:00 amRNSDirector Share Purchase
23rd Aug 20227:00 amRNSDirectorate Change
16th Aug 20227:00 amRNSInterim Results
29th Jul 20227:00 amRNSChange of Adviser
20th Jul 20224:08 pmRNSDirector/PDMR Dealing
11th Jul 20227:00 amRNSTrading Update
29th Jun 20223:15 pmRNSDirector/PDMR Shareholding
23rd Jun 202212:14 pmRNSResult of AGM
7th Jun 20228:59 amRNSHolding(s) in Company
25th May 20227:00 amRNSFinal 2021 Results and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.